TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
about
Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.Molecular therapy for acute myeloid leukaemia.Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesAnti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Progression inference for somatic mutations in cancer.Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.TP53 mutations in older adults with acute myeloid leukemia.Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia.Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia.High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis.Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome.Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology.GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia
P2860
Q33746746-D8788928-BC8F-4274-A8EA-B4E4569F77E6Q33925672-D688E1DC-8509-41D7-89E5-DFCBB2D19377Q36962514-6F7678EC-195E-4B12-83BD-1B5F32EAC64EQ37566878-6FDDCF1C-1E40-4CD5-AF3F-65421AAEA8DEQ37603441-9E29A773-978F-4E24-8967-013E0F3D7643Q37665288-6FBE2D45-6ACB-4C92-830F-7CFE04D319E5Q38650669-94AA61D4-6366-4D4A-8ABF-26303C3E784BQ38703904-82434B43-95EE-431A-BD76-ABB758640F79Q38793244-0BC8ACFE-D8E6-4D3E-96FD-C889A7119193Q39295844-C42FA7D0-570E-4429-9744-DECB668ACC9CQ39555179-3F08BE06-1102-42F3-B569-D5F63A406508Q40967841-9CA7DAB1-B89C-4530-8EC1-68FAF0DE8C5DQ41316658-218E5B2B-DAAB-4A1F-8CA9-D45942B9D311Q42324235-FFB164DE-5368-4A1F-BA77-25ED8F39FBB0Q42700810-F7D4A7F8-9F65-4972-9F8E-52EE77D55561Q44176860-79139771-914E-498C-8C7C-101DBD08509DQ47136441-4B6F7763-BC5E-496B-93B3-8D121F8B7222Q47142820-0B5A1DDA-D36D-4BDE-AE45-3C5C1BA4A706Q48216923-265A6A67-9F1D-46A1-B815-BB140E9C70B3Q48242145-7F12B194-0BA9-4331-8336-4AE0A8A93AE2Q49164595-6071AF79-3269-4A1F-BD35-06F10F25ACB4Q50090381-F9708AB7-06D6-4F57-A8B2-F90E7572DCB7Q52721521-6D6FCA72-7412-4194-B20B-3DCF084EFEC9Q52777531-1B3E53F1-33C5-469E-A25C-2921D4ACB3D0Q53064376-64DEFBBA-1C36-4A00-9F74-06B019AD35C2Q55009819-4406798E-E220-419F-9F24-3BAB826F766CQ55025720-779E2C09-BBED-4FE2-8F77-DF863254B3C5Q55394255-836BA73E-A4F2-4706-A670-5017DA69B90EQ58781139-B782B39D-5C8A-4F9A-B0B2-6B4546B78618
P2860
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
TP53 mutations in de novo acut ...... able during disease evolution.
@ast
TP53 mutations in de novo acut ...... able during disease evolution.
@en
type
label
TP53 mutations in de novo acut ...... able during disease evolution.
@ast
TP53 mutations in de novo acut ...... able during disease evolution.
@en
prefLabel
TP53 mutations in de novo acut ...... able during disease evolution.
@ast
TP53 mutations in de novo acut ...... able during disease evolution.
@en
P2093
P2860
P50
P356
P1433
P1476
TP53 mutations in de novo acut ...... table during disease evolution
@en
P2093
P2860
P2888
P356
10.1038/BCJ.2015.59
P50
P577
2015-07-31T00:00:00Z